Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children_老虎社区_美港股上老虎

Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children

seekingalpha2023-04-28

A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

蓬砰嘭
·2023-05-04
这篇文章不错，转发给大家看看
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2330415875?lang=zh_CN&edition=full","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/840444054/image_840444054.jpg","is_english":true,"pubTime":"2023-04-28 17:57","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2330415875","market":"us","top_or_hot":-1,"title":"Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children","media":"seekingalpha","content":"<div>\n<p>A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. ...</p>\n\n<a href=\"https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Adempas for high blood pressure in lungs gets EMA nod for use in children\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-28 17:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. ...</p>\n\n<a href=\"https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids","article_id":"2330415875","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/840444054/image_840444054.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2330415875","pubTimestamp":1682675863,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4201":"综合性石油与天然气企业","BK4123":"调查和咨询服务","BK4007":"制药","EC":"哥伦比亚国家石油","CHMP":"冠军工业","BK4087":"商业印刷","BAYZF":"Bayer A.G.","FC":"富兰克林柯维"},"translate_title":"拜耳公司治疗肺部高血压的Adempas获得EMA批准用于儿童","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"BAYZF":1,"CHMP":1,"EC":1,"FC":1},"content_text":"A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. Pulmonary hypertension is a type of high blood pressure which affects the arteries in the lungs and the right side of the heart. In PAH the blood vessels in the lungs are narrowed, blocked or destroyed which slows down blood flow in the lungs and blood pressure in the lung arteries rises.  The EMA's Committee for Medicinal Products for Human Use (CHMP) backed the use of Adempas (riociguat) to treat PAH in pediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) 2 to 3 in combination with endothelin receptor antagonists. Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated to treat adults with PAH, the CHMP noted. The European Commission (EC) will now make a final call on the change to the marketing authorization of the drug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":656009467,"gmtCreate":1683178381859,"gmtModify":1683178432145,"author":{"id":"3503036325672104","authorId":"3503036325672104","name":"蓬砰嘭","avatar":"https://static.tigerbbs.com/229223b54a06fc1bf2fe80f3062c16bc","vip":1,"hat":"https://static.tigerbbs.com/e1c01e958f63198f5d9648b59135f687","crmLevel":2,"crmLevelSwitch":0,"idStr":"3503036325672104","authorIdStr":"3503036325672104"},"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/656009467","repostId":2330415875,"repostType":2,"repost":{"id":"2330415875","kind":"highlight","pubTimestamp":1682675863,"share":"https://www.laohu8.com/m/news/2330415875?lang=&edition=full","pubTime":"2023-04-28 17:57","market":"us","language":"en","title":"Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children","url":"https://stock-news.laohu8.com/highlight/detail?id=2330415875","media":"seekingalpha","summary":"A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK","content":"<html><body><ul> <li>A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children.</li> <li>Pulmonary hypertension is a type of high blood pressure which affects the arteries in the lungs<span> and the right side of the heart. In PAH the blood vessels in the lungs are narrowed, blocked or destroyed which slows down blood flow in the lungs and blood pressure in the lung arteries rises.</span> </li> <li>The EMA's Committee for Medicinal Products for Human Use (CHMP) backed the use of Adempas (riociguat) to treat PAH in pediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) 2 to 3 in combination with endothelin receptor antagonists.</li> <li>Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated to treat adults with PAH, the CHMP noted.</li> <li>The European Commission (EC) will now make a final call on the change to the marketing authorization of the drug.</li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Adempas for high blood pressure in lungs gets EMA nod for use in children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Adempas for high blood pressure in lungs gets EMA nod for use in children\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-28 17:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. ...</p>\n\n<a href=\"https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/840444054/image_840444054.jpg","relate_stocks":{"BK4007":"制药","FC":"富兰克林柯维","BAYZF":"Bayer A.G.","CHMP":"冠军工业","BAYRY":"Bayer A.G.","EC":"哥伦比亚国家石油","BK4201":"综合性石油与天然气企业","BK4123":"调查和咨询服务","BK4087":"商业印刷"},"source_url":"https://seekingalpha.com/news/3961907-bayer-adempas-for-high-blood-pressure-in-lungs-gets-ema-nod-for-use-in-kids","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2330415875","content_text":"A committee of the European Medicines Agency (EMA) recommended the expanded approval of Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) pulmonary arterial hypertension (PAH) drug Adempas for use in children. Pulmonary hypertension is a type of high blood pressure which affects the arteries in the lungs and the right side of the heart. In PAH the blood vessels in the lungs are narrowed, blocked or destroyed which slows down blood flow in the lungs and blood pressure in the lung arteries rises.  The EMA's Committee for Medicinal Products for Human Use (CHMP) backed the use of Adempas (riociguat) to treat PAH in pediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) 2 to 3 in combination with endothelin receptor antagonists. Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated to treat adults with PAH, the CHMP noted. The European Commission (EC) will now make a final call on the change to the marketing authorization of the drug.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}